Table 1. Incidence Proportion and Median Survival of Patients With Breast Cancer With Identified Brain Metastases at Diagnosis by Subtype.
| Subtype | Patients, No. | Incidence Proportion of Brain Metastases, % | Survival Among Patients With Brain Metastases, Median (IQR), mo | |||
|---|---|---|---|---|---|---|
| With Breast Cancer | With Metastatic Disease | With Brain Metastases | Among Entire Cohort | Among Subset With Metastatic Disease | ||
| HR+/HER2− | 162 078 | 6607 | 361 | 0.22 | 5.46 | 14.0 (4.0-34.0) |
| HR+/HER2+ | 22 376 | 1704 | 136 | 0.61 | 7.98 | 21.0 (6.0-NR) |
| HR−/HER2+ | 9719 | 926 | 106 | 1.09 | 11.45 | 10.0 (4.0-27.0) |
| Triple-negative | 25 362 | 1522 | 173 | 0.68 | 11.37 | 6.0 (2.0-13.0) |
| Unknown | 19 191 | 2042 | 192 | 1.00 | 9.40 | 6.0 (2.0-20.0) |
| All subtypes | 238 726 | 12 801 | 968 | 0.41 | 7.56 | 10.0 (3.0-30.0) |
Abbreviations: HER2, human epidermal growth factor receptor 2; HR, hormone receptor; IQR, interquartile range; NR, not reached. + Denotes positive; − denotes negative.